Incorporating a polygenic risk score into prostate cancer screening could enhance the detection of clinically significant prostate cancer that conventional screening may miss, according to results of ...

A prostate cancer screening program involving participants in the top decile of risk according to a polygenic risk score identifies clinically significant disease, according to a study published in ...

Nearly all men with a polygenic risk score in the 90th percentile or above had a 10-year absolute risk for prostate cancer exceeding 3.8%. A polygenic risk score (PRS) identifies more patients with ...

The Stockholm3 model combines PSA, plasma protein biomarkers, polygenic risk, and clinical factors for prostate cancer screening.

A polygenic risk score was able to detect a high proportion of clinically significant prostate cancer. Cancer would not have been detected in 71.8% of patients with the use of PSA or MRI screening.

Stockholm3, which combines prostate-specific antigen (PSA), plasma protein biomarkers, polygenic risk, and clinical factors offers greater clinical net benefit for detecting clinically significant ...

A family history of prostate cancer has long been one of the few universally accepted risk factors for the disease. New findings now provide evidence that risk stratification based on family history ...

Optimizing the Systemic Treatment for Metastatic Castration-Resistant Prostate Cancer in Lower-Middle–Income Countries: A 7-Year Analysis of the Brazilian Public Health System African ancestry and ...

New prostate cancer research from an international team led by the Center for Genetic Epidemiology at the Keck School of Medicine of USC has yielded discoveries that could improve screening and ...